Abstract
Atypical fracture of the femur is a well-documented adverse reaction to antiresorptive treatment with bisphosphonates. Although there has been significant gain of knowledge during the past decade, the pathogenesis of this type of fracture is still poorly understood. We present an update on the evidence in regard to epidemiology, pathophysiology, and management of atypical fractures.
MeSH terms
-
Aged
-
Bone Density Conservation Agents / adverse effects*
-
Diphosphonates / adverse effects*
-
Diphosphonates / therapeutic use
-
Evidence-Based Medicine
-
Female
-
Femoral Fractures / chemically induced*
-
Femoral Fractures / diagnostic imaging
-
Femoral Fractures / physiopathology
-
Femoral Fractures / prevention & control
-
Humans
-
Male
-
Radiography
-
Risk Factors
Substances
-
Bone Density Conservation Agents
-
Diphosphonates